{"protocolSection": {"identificationModule": {"nctId": "NCT02548650", "orgStudyIdInfo": {"id": "IIS 53377"}, "organization": {"fullName": "University of Florida", "class": "OTHER"}, "briefTitle": "Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus", "officialTitle": "Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study", "acronym": "OPTIMUS-5"}, "statusModule": {"statusVerifiedDate": "2020-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-03-25", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-02-14", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-09-08", "studyFirstSubmitQcDate": "2015-09-11", "studyFirstPostDateStruct": {"date": "2015-09-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-01-10", "resultsFirstSubmitQcDate": "2020-01-10", "resultsFirstPostDateStruct": {"date": "2020-01-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-01-29", "lastUpdatePostDateStruct": {"date": "2020-02-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Florida", "class": "OTHER"}, "collaborators": [{"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI) or peripheral arterial disease (PAD). However, rates of ischemic recurrences remain high. Vorapaxar is a protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of thrombin-mediated platelet aggregation. Patients with diabetes mellitus (DM) are known to be at increased risk of recurrent atherothrombotic events, which translates into worse outcomes, despite the use of standard of care therapy. This is in part due to the hyperreactive platelet phenotype, which characterizes DM patients, and to inadequate response to oral antiplatelet agents, including clopidogrel. Therefore, vorapaxar is an attractive treatment option for DM patients with a prior MI. The pharmacodynamic (PD) effects of vorapaxar in DM patients and how these may differentiate from non-DM patients has not been explored. Further, the role of vorapaxar as part of a dual antithrombotic treatment regimen combined with clopidogrel (and stopping aspirin) represents another important area of clinical interest. The proposed prospective, parallel-design study conducted in patients post-MI or with PAD with and without DM will aim the assess the pharmacodynamic effects of vorapaxar in addition to standard DAPT with aspirin and clopidogrel as well as in combination with clopidogrel only following aspirin withdrawal.", "detailedDescription": "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI) or peripheral arterial disease (PAD). However, rates of ischemic recurrences remain high, in part due to the fact that other platelet signaling pathways, such as thrombin-induced platelet aggregation, continue to be activated. Vorapaxar is a novel, orally active, competitive and slowly reversible protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of thrombin-mediated platelet aggregation. It is approved for clinical use by the Food and Drug Administration for the reduction of thrombotic cardiovascular events in patients with a history of MI or with peripheral arterial disease. Patients with DM are known to be at increased risk of recurrent atherothrombotic events, which translates into worse outcomes, despite the use of standard of care therapy. This is in part due to the hyperreactive platelet phenotype, which characterizes DM patients, and to inadequate response to oral antiplatelet agents, including clopidogrel. Importantly, in DM patients with prior MI included in the TRA 2P trial, vorapaxar reduced the primary composite end point at 3 years by 27% and led to a greater absolute risk reduction compared with those without DM. Therefore, vorapaxar is an attractive treatment option for DM patients with a prior MI. However, to date the PD effects of vorapaxar in DM patients and how these may differentiate from non-DM patients has not been explored. Further, current trends in clinical practice are seeing many patients discontinue aspirin and maintain clopidogrel. Hence, the role of vorapaxar as part of a dual antithrombotic treatment regimen combined with clopidogrel (and stopping aspirin) represents another important area of clinical interest, in order to maximize ischemic protection while reducing the risk of bleeding. The proposed prospective, parallel-design study conducted in patients post-MI or with PAD with and without DM will aim the assess the pharmacodynamic effects of vorapaxar in addition to standard DAPT with aspirin and clopidogrel as well as in combination with clopidogrel only following aspirin withdrawal. Pharmacodynamic assessments will be performed at multiple time point, with different assays exploring multiple pathways of platelet aggregation."}, "conditionsModule": {"conditions": ["Myocardial Infarction", "Diabetes Mellitus", "Peripheral Arterial Disease"], "keywords": ["myocardial infarction", "diabetes mellitus", "vorapaxar", "peripheral arterial disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 66, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with diabetes", "type": "EXPERIMENTAL", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.", "interventionNames": ["Drug: Vorapaxar", "Drug: Clopidogrel", "Drug: Aspirin"]}, {"label": "Patients without diabetes", "type": "ACTIVE_COMPARATOR", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.", "interventionNames": ["Drug: Vorapaxar", "Drug: Clopidogrel", "Drug: Aspirin"]}], "interventions": [{"type": "DRUG", "name": "Vorapaxar", "description": "Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days", "armGroupLabels": ["Patients with diabetes", "Patients without diabetes"], "otherNames": ["Zontivity"]}, {"type": "DRUG", "name": "Clopidogrel", "description": "Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days", "armGroupLabels": ["Patients with diabetes", "Patients without diabetes"], "otherNames": ["Plavix"]}, {"type": "DRUG", "name": "Aspirin", "description": "Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days", "armGroupLabels": ["Patients with diabetes", "Patients without diabetes"], "otherNames": ["ASA"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximal Platelet Aggregation in DM", "description": "Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy in diabetic patients", "timeFrame": "30 days"}], "secondaryOutcomes": [{"measure": "Maximal Platelet Aggregation in Non-DM", "description": "Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy in non-diabetic patients", "timeFrame": "30 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Patients with a prior MI between 2 weeks and 24 months or with PAD.\n2. On DAPT with low-dose aspirin (81mg od) and clopidogrel (75mg od) as per standard-of-care for at least 14 days.\n3. Age \u2265 18 years old.\n\nExclusion criteria:\n\n1. History of acute coronary syndrome in the previous 2 weeks.\n2. History of stroke, transient ischemic attack, or intracranial hemorrhage.\n3. Active pathological bleeding, history of bleeding events or increased risk of bleeding.\n4. Known severe hepatic impairment.\n5. Use of strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) or inducers (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin).\n6. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban).\n7. On treatment with any antiplatelet agent other than aspirin and clopidogrel in the past 14 days.\n8. Creatinine clearance \\<30 mL/minute.\n9. Platelet count \\<80x106/mL\n10. Hemoglobin \\<10g/dL\n11. Hemodynamic instability\n12. Pregnant females", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dominick J Angiolillo, MD, PhD", "affiliation": "University of Florida College of Medicine-Jacksonville", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Florida", "city": "Jacksonville", "state": "Florida", "zip": "32209", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}]}, "referencesModule": {"references": [{"pmid": "31998847", "type": "DERIVED", "citation": "Franchi F, Rollini F, Kairouz V, Rivas Rios J, Rivas A, Agarwal M, Briceno M, Wali M, Nawaz A, Silva G, Shaikh Z, Maaliki N, Been L, Piraino J, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Jennings LK, Bass TA, Angiolillo DJ. Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study. JACC Basic Transl Sci. 2019 Sep 1;4(7):763-775. doi: 10.1016/j.jacbts.2019.07.011. eCollection 2019 Nov."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Between March 2016 and October 2018, 71 patients agreed to participate in the study; 5 patients were not eligible for randomization due to the presence of an exclusion criteria. 66 patients (DM, n=30; non-DM, n=36) were exposed to at least one dose of study medication, representing the safety population.", "groups": [{"id": "FG000", "title": "Patients With Diabetes", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days."}, {"id": "FG001", "title": "Patients Without Diabetes", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days."}], "periods": [{"title": "Triple Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}]}]}, {"title": "Double Therapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Two patients were not compliant with medications and therefore excluded from the PD analysis. Thus, a total of 64 patients (DM, n=30; non-DM, n=34) represented the PD population of the study and were analyzed for baseline characteristics and PD data.", "groups": [{"id": "BG000", "title": "Patients With Diabetes", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days."}, {"id": "BG001", "title": "Patients Without Diabetes", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "64"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61", "spread": "8"}, {"groupId": "BG001", "value": "56", "spread": "9"}, {"groupId": "BG002", "value": "58", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "25"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "37"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "chronic kidney disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximal Platelet Aggregation in DM", "description": "Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy in diabetic patients", "populationDescription": "The PD population included all patients with PD data and without a major protocol deviation thought to affect the PD effects of vorapaxar, aspirin and clopidogrel. Two patients were not compliant with medications and therefore excluded from the PD analysis. Some patients did not have primary end point data but were considered for other analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of aggregation", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Triple Therapy", "description": "vorapaxar plus DAPT"}, {"id": "OG001", "title": "Dual Therapy", "description": "(vorapaxar plus clopidogrel)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65", "spread": "20"}, {"groupId": "OG001", "value": "78", "spread": "20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The primary end point of our study was the comparison of CAT-induced MPA measured by LTA between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy. We hypothesized that dual therapy would be non-inferior to triple therapy after 30\u00b15 days of treatment", "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Under the null hypothesis that the mean aggregation between dual and triple therapy is not equal to 0 and a common standard deviation of 13%, a sample size of 28 patients per group with a valid primary end point time point allowed for the 95% confidence interval (CI) to stay within \u00b1 10% with a 80% power and a two-sided alpha=0.05.", "pValue": ">0.05", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Net)", "paramValue": "12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3", "ciUpperLimit": "21"}]}, {"type": "SECONDARY", "title": "Maximal Platelet Aggregation in Non-DM", "description": "Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy in non-diabetic patients", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of aggregation", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Triple Therapy", "description": "vorapaxar plus DAPT"}, {"id": "OG001", "title": "Dual Therapy", "description": "(vorapaxar plus clopidogrel)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "60", "spread": "15"}, {"groupId": "OG001", "value": "70", "spread": "20"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Study duration (60 days)", "eventGroups": [{"id": "EG000", "title": "Patients With Diabetes", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 30, "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 2, "otherNumAtRisk": 30}, {"id": "EG001", "title": "Patients Without Diabetes", "description": "Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.", "deathsNumAffected": 0, "deathsNumAtRisk": 36, "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 2, "otherNumAtRisk": 36}], "otherEvents": [{"term": "minor bleeding", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "hematuria", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 36}]}, {"term": "Chest pain", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "chest pain not requiring intervention", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 36}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dominick J Angiolillo", "organization": "University of Florida College of Medicine - Jacksonville", "email": "dominick.angiolillo@jax.ufl.edu", "phone": "9042443933"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-10-02", "uploadDate": "2020-01-08T16:17", "filename": "Prot_SAP_000.pdf", "size": 314948}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000058729", "term": "Peripheral Arterial Disease"}, {"id": "D000016491", "term": "Peripheral Vascular Diseases"}, {"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000050197", "term": "Atherosclerosis"}, {"id": "D000001161", "term": "Arteriosclerosis"}, {"id": "D000001157", "term": "Arterial Occlusive Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M29213", "name": "Peripheral Arterial Disease", "asFound": "Peripheral Arterial Disease", "relevance": "HIGH"}, {"id": "M18894", "name": "Peripheral Vascular Diseases", "asFound": "Peripheral Arterial Disease", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M26188", "name": "Atherosclerosis", "relevance": "LOW"}, {"id": "M4469", "name": "Arteriosclerosis", "relevance": "LOW"}, {"id": "M4465", "name": "Arterial Occlusive Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001241", "term": "Aspirin"}, {"id": "D000077144", "term": "Clopidogrel"}, {"id": "C000530299", "term": "Vorapaxar"}], "ancestors": [{"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000005343", "term": "Fibrinolytic Agents"}, {"id": "D000050299", "term": "Fibrin Modulating Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000058633", "term": "Antipyretics"}, {"id": "D000058921", "term": "Purinergic P2Y Receptor Antagonists"}, {"id": "D000058919", "term": "Purinergic P2 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "asFound": "Baseline", "relevance": "HIGH"}, {"id": "M1669", "name": "Clopidogrel", "asFound": "Adjuvant", "relevance": "HIGH"}, {"id": "M232630", "name": "Vorapaxar", "asFound": "Diabetes Type 2", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M29176", "name": "Antipyretics", "relevance": "LOW"}, {"id": "M29294", "name": "Purinergic P2Y Receptor Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}